Subject: Re: Bamlanivimab supply for Georgia
From: Tengiz Tsertsvadze <[email-masked]>
To: "[email-masked]" <[email-masked]>
Cc: "[email-masked]" <[email-masked]>, Ekaterine Adamia <[email-masked]>, Maia Nikoleishvili <[email-masked]>, [email-masked], Alisa Tsuladze <[email-masked]>, [email-masked], akaki abutidze <[email-masked]>
Date: Mon, 22 Mar 2021 08:17:34 +0000

Dear Dr. Petrov,

I hope this email finds you well. Attached please find a draft of the agreement. We would appreciate your comments.

Thank you once again for your generous support and we look forward to receiving your response.

Best regards,

Tengiz Tsertsvadze MD, PhD

Director General

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi

On Tue, Mar 16, 2021 at 12:39 AM Tengiz Tsertsvadze <[email-masked]> wrote:

Dear Dr. Petrov,

I hope this email finds
you well. Once again we would like to express our sincere gratitude personally
to you and company Eli Lilly for considering the opportunity for emergency use authorization
for Bamlanivimab in Georgia. As we mentioned
earlier this is one of the most promising methods of COVID-19 treatment and we
would highly appreciate your generous collaboration in this matter.

We do apologize
for our delayed response due to our very busy schedule over the last weeks.

As we understood
from our teleconference with you, company Eli Lilly considers the opportunity to donate some
quantity of Bamlanivimab to Georgia.

In order to obtain
approval from the regulatory agency to conduct a clinical trial, together with ministry
of health officials we have already started preparation work for the submission
package. For this we kindly ask you to provide necessary documents on the investigational
product, including FDA approval, preclinical materials, GMP certificates and other
relevant documents.

Also, it has been decided that our center (Infectious
Diseases, AIDS and Clinical Immunology Research Center, which is Georgia’s referral
institution for treatment and care of all infectious diseases, including HIV/AIDS,
viral hepatitis and COVID-19) will be responsible for receiving Bamlanivimab from
your company. In this regard it is necessary to formalize an agreement between
our center and company Eli Lilly. Tomorrow we will provide you a draft of the
agreement and would appreciate your comments. My colleagues (cc'd) are
ready to work on the agreement document.

Thank you
very much in advance for your kind consideration.

Best
regards,

Tengiz
Tsertsvadze MD, PhD

Director
General

Infectious Diseases,
AIDS and Clinical Immunology Research Center, Tbilisi

On Sun, Jan 31, 2021 at 1:49 PM Alisa Tsuladze <[email-masked]> wrote:

Dear Dr. Petrov,

First of all we would like to thank you for your letter and your kind suggestion to help us receive Bamlanivimab. We have discussed this opportunity with the  COVID-19 national clinical group of experts
and are interested in all novel monoclonal antibodies in general and Bamlanivimab in particular. We
think that this is one of the most promising methods of COVID-19 treatment.

However, we will need more information about the medicine, such as the available interim results from different countries where it is being used. Also we would like to request more information about organizing
supply of the medicine to our country.  As for the local regulatory approval, we will proceed with the authorization as soon as we have additional information.

For this reasons we think that it would be helpful for both sides to organize an online meeting to discuss all the matters.

Thank you for your time and consideration, looking forward to your reply.

Respectfully,

Alisa Tsuladze, MPH

Health Policy Division

Policy Department

Ministry of Internally Displaced persons from

Occupied Territories, Labor, Health and Social Affairs of Georgia

Tel.: +995-32-2-51-00-38  ext 1125